when was the first glp 1 agonist approved of GLP-1RAs for treatment of type 2 diabetes. FDA US Food Another milestone in the evolution
Description
Key Findings: - Increased risk of going over recommended weight gain limits - Higher chances of preterm birth (from 13% to 17%) - Rising cases of gestational diabetes (15% to 20%) - Nearly half faced high blood pressure issues While baby sizes and C-section rates remained similar, the impact on maternal health is significant

Designed to complement your GLP-1 journey

The best results happen when the medicine is used along with healthy eating and exercise, and people may gain weight back if they stop taking the medicine

Rheumatology insights & real results.

No injections

This new pill contains the same active ingredient as injectable Wegovy and Ozempic, semaglutide
